Drug intelligence / Profile preview

AS03B (GSK)

Development stage: Unknown
Lead developer: GSK
Modality: Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intramuscular

Overview

**AS03B** is GSK's half-dose AS03 oil-in-water vaccine adjuvant system. It contains 5.93 mg of DL-alpha-tocopherol per dose, compared with 11.86 mg in AS03A, and includes squalene as an emulsion component. AS03B is administered with, rather than independently of, vaccine antigen to enhance antigen-specific immune responses. It has been evaluated with monovalent inactivated split-virion influenza A H7N9 vaccine formulations in healthy adults; in these studies, AS03A generally produced stronger humoral responses than AS03B, particularly among older adults. ([cdn.clinicaltrials.gov](https://cdn.clinicaltrials.gov/large-docs/77/NCT04789577/Prot_000.pdf))

Beyond the preview

Go deeper on AS03B (GSK).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AS03B (GSK).

Explore the full profile